KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Short-term Investments (2020 - 2025)

Royalty Pharma's Short-term Investments history spans 6 years, with the latest figure at $18.8 million for Q4 2025.

  • For Q4 2025, Short-term Investments fell 67.7% year-over-year to $18.8 million; the TTM value through Dec 2025 reached $18.8 million, down 67.7%, while the annual FY2025 figure was $18.8 million, 67.7% down from the prior year.
  • Short-term Investments for Q4 2025 was $18.8 million at Royalty Pharma, up from $16.1 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $409.3 million in Q3 2022 and bottomed at $1.3 million in Q4 2022.
  • The 5-year median for Short-term Investments is $33.8 million (2024), against an average of $68.8 million.
  • The largest YoY upside for Short-term Investments was 1307.69% in 2023 against a maximum downside of 98.71% in 2023.
  • A 5-year view of Short-term Investments shows it stood at $66.0 million in 2021, then crashed by 98.03% to $1.3 million in 2022, then surged by 1307.69% to $18.3 million in 2023, then skyrocketed by 218.03% to $58.2 million in 2024, then plummeted by 67.7% to $18.8 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Short-term Investments are $18.8 million (Q4 2025), $16.1 million (Q3 2025), and $13.2 million (Q2 2025).